Welcome to our dedicated page for Ramm Pharma news (Ticker: RAMMF), a resource for investors and traders seeking the latest updates and insights on Ramm Pharma stock.
RAMM PHARMA CORP (RAMMF) delivers pharmaceutical innovations through rigorously validated research and strategic academic partnerships. This news hub provides investors and healthcare professionals with essential updates on the company's scientific advancements and regulatory progress.
Access timely updates on clinical trial developments, regulatory submissions, and research collaborations. Our curated news collection ensures stakeholders stay informed about RAMMF's evidence-based approach to drug development and quality-controlled manufacturing processes.
Key updates include progress reports on therapeutic formulations, partnership announcements with research institutions, and compliance milestones in global pharmaceutical markets. All content reflects the company's commitment to transparency and scientific validation through peer-reviewed methodologies.
Bookmark this page for direct access to official RAMMF communications, including analysis of research outcomes and strategic initiatives. Regularly updated to serve as your primary resource for understanding the company's position in pharmaceutical innovation.
RAMM Pharma (CSE: RAMM / OTC: RAMMF) announced minority shareholders approved a proposed investment in The Global South S.A.S. at a Special Meeting on November 12, 2025. The Company will invest US$5.0 million for a 10% equity stake based on a post-investment valuation of US$50,000,000. RAMM will also receive a five-year call option to buy an additional 15% (bringing total ownership to 25%) at a future post-money valuation of US$400,000,000. The Company currently lacks the funds to close and is evaluating financing options; completion remains subject to definitive agreements and regulatory approvals.
RAMM Pharma (CSE:RAMMF) disclosed supplemental details for its proposed transaction with The Global South S.A.S ahead of the Special Meeting on November 12, 2025. RAMM proposes a US$5.0M investment for 10% of Global South (post-money valuation US$50M) and a five-year call option to increase ownership to 25% at a future post-money valuation of US$400M. The transaction is related-party (Global South owned by CEO Jackie Peter Burnett); Burnett and another officer will be excluded from voting, representing 22.57% ownership. RAMM currently lacks funds to close and expects to complete the transaction within nine months, subject to approvals and definitive documentation.
RAMM Pharma (CSE: RAMMF) notified shareholders on Oct 22, 2025 that Canada Post strike disruptions may delay delivery of proxy and meeting materials for the Special Meeting of Shareholders on Nov 12, 2025 at 2:30 p.m. Toronto time.
The Meeting Materials are available electronically on SEDAR+ and via Odyssey Trust at https://odysseytrust.com/client/ramm-pharma-corp-spc/. While materials were mailed, delivery before the meeting is not assured due to partial mail service and potential delays.
Registered shareholders can request a control number or voting help via Odyssey Trust’s chat or by calling 1-888-290-1175 (North America toll-free) or 1-587-885-0960 (outside North America). Beneficial shareholders should contact their brokerage or intermediary to request a proxy.
RAMM Pharma Corp. has updated its shareholders on ongoing litigation involving Sergio Martines and Naturale Science Inc. The trial occurred between April 29, 2024, and May 16, 2024, with the judge reserving the decision. Martines and Naturale Science Inc. are demanding approximately C$3 million from RAMM for breach of contract, specific performance, and out-of-pocket expenses. In response, RAMM has filed a counterclaim seeking C$14 million in damages for alleged fraudulent misrepresentation related to its acquisition of Canapar in June 2021. RAMM has accrued C$300,000 in its financial statements for possible liabilities, which may be adjusted in future reports.
